HOLON, Israel, March 11,
2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN)
(TASE: CGEN) a clinical-stage cancer immunotherapy company and a
pioneer in computational target discovery, today announced that it
has been selected to give two oral presentations at the Keystone
Symposium on Cancer Immunotherapy: Beyond Immune Checkpoint
Blockade and Overcoming Resistance, taking place March 17-21, 2024, in Whistler, Canada.
"We are delighted to be selected to give two oral presentations
at the upcoming Keystone Symposium on Cancer Immunotherapy this
year," said Anat Cohen-Dayag, Ph.D.,
President, and CEO of Compugen. "We believe our selection to
present at a Keystone Symposium reflects the significant discovery,
research and development taking place at Compugen as we are working
to advance our vision to transform patient lives by developing
first-in class therapeutics based on our computational target
discovery platform."
|
Presentation &
poster details
|
|
Oral presentation
date:
|
Tuesday, March 19,
2024
|
|
Session title:
|
Novel insights into T
Cell Biology
|
|
Lead author and
presenter:
|
Dr. Assaf Menachem,
Ph.D., Compugen
|
|
Presentation &
poster title:
|
Unleashing Natural
IL-18 Activity Using an Anti-IL-18BP Blocker Antibody
Induces Potent Immune
Stimulation and Anti-tumor
Effects
|
|
Poster date:
|
Tuesday, March 19,
2024
|
|
Poster number:
|
Poster #2042
|
|
|
|
|
|
Oral presentation
date:
|
Tuesday, March 19,
2024
|
|
Oral session
title:
|
Progress in Drugging
the TIGIT and VISTA Pathways
|
|
Lead author and
presenter:
|
Dr. Zoya Alteber,
Ph.D., Compugen
|
|
Presentation &
poster title:
|
PVRIG is Uniquely
Expressed in Tumor Dendritic Cell-rich Niches on Stem-like Memory T
Cells and
its Blockade May Induce Immune Infiltration and Activation in
Non-inflamed Tumors
|
|
Poster date:
|
Monday, March 18,
2024
|
|
Poster number:
|
Poster #1001
|
The abstracts are available on the publication section of
Compugen's website www.cgen.com.
The presentations and posters will be made available on
www.cgen.com, on the day of presentation.
About Compugen
Compugen is a clinical-stage therapeutic discovery and
development company utilizing its broadly applicable predictive
computational discovery capabilities to identify new drug targets
and biological pathways for developing cancer
immunotherapies. Compugen has developed two proprietary
product candidates: COM701, a potential first-in-class anti-PVRIG
antibody and COM902, a potential best-in-class antibody
targeting TIGIT for the treatment of solid tumors. Compugen also
has a clinical stage partnered program, rilvegostomig (previously
AZD2936), a PD-1/TIGIT bispecific antibody where the TIGIT
component is derived from Compugen's clinical stage anti-TIGIT
antibody, COM902, in Phase 3 development by AstraZeneca through a
license agreement for the development of bispecific and
multispecific antibodies. In addition, Compugen's therapeutic
pipeline of early-stage immuno-oncology programs consists of
programs aiming to address various mechanisms of immune resistance,
of which the most advanced program, in IND enabling studies is
COM503, which is licensed to Gilead. COM503 is a potential
first-in-class, high affinity antibody which blocks the interaction
between IL-18 binding protein and IL-18, thereby freeing natural
IL-18 in the tumor microenvironment to inhibit cancer growth.
Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are
listed on Nasdaq and the Tel Aviv Stock Exchange under the
ticker symbol CGEN.
Company contact:
Yvonne Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original
content:https://www.prnewswire.com/news-releases/compugen-selected-for-two-oral-presentations-at-the-keystone-symposium-on-cancer-immunotherapy-302085114.html
SOURCE Compugen Ltd.